

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-22. (Canceled)

23. (Currently Amended) An isolated cell having a lipidated protein incorporated into the cell membrane, said lipidated protein having bound thereto a fusion protein, said fusion protein ~~consisting of a first domain and a second domain, said second domain encoding a protein~~ having a costimulatory, inhibitory or adhesion function.

Claims 24-50 (Canceled)

51. (Previously Presented) The cell of Claim 23, wherein said lipidated protein is selected from the group consisting of lipidated protein A and lipidated protein G.

52. (Previously Presented) The cell of Claim 23, wherein said lipidated protein is palmitated protein A.

Claims 53-54 (Canceled)

55. (Currently Amended) The cell of Claim 23, wherein ~~said second domain encodes the protein having a costimulatory, inhibitory or adhesion function~~ is a type I membrane protein.

56. (Currently Amended) The cell of Claim 23, wherein ~~said second domain encodes the protein having a costimulatory, inhibitory or adhesion functions~~ is a type II membrane protein.

Claims 57-58 (Canceled)

59. (Previously Presented) The cell of Claim 23, wherein said costimulatory protein is selected from the group consisting of B7-1, B7-2, ICAM-1, ICAM-2, ICAM-3, CD48, LFA-3, 4-1BB ligand, CD30 ligand, CD40 ligand, and heat stable antigen.

60. (Previously Presented) The cell of Claim 59, wherein said fusion protein is B7-Fc γ_1 .

61. (Previously Presented) The cell of Claim 23, wherein said inhibitory protein is selected from the group consisting of CD8, Fas ligand and a single chain Fv derivative of immunoglobulin.